Skip to main content
SpringerLink
Log in

Oral targeted therapies for CLL impose financial burden

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. 2015 US dollars

Reference

  • Chen Q, et al. Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States. Journal of Clinical Oncology : JCO2016682856, 12 Nov 2016. Available from: URL: http://doi.org/10.1200/JCO.2016.68.2856

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Oral targeted therapies for CLL impose financial burden. PharmacoEcon Outcomes News 767, 24 (2016). https://doi.org/10.1007/s40274-016-3584-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-3584-1

Search

Navigation